NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
22.09
+0.44 (2.03%)
Feb 21, 2025, 4:00 PM EST - Market closed
NovoCure Revenue
NovoCure had revenue of $155.10M in the quarter ending September 30, 2024, with 21.81% growth. This brings the company's revenue in the last twelve months to $577.74M, up 14.63% year-over-year. In the year 2023, NovoCure had annual revenue of $509.34M, down -5.30%.
Revenue (ttm)
$577.74M
Revenue Growth
+14.63%
P/S Ratio
4.11
Revenue / Employee
$397,617
Employees
1,453
Market Cap
2.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.66M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | 351.32M | 103.25M | 41.62% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
NVCR News
- 4 weeks ago - Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland - Business Wire
- 5 weeks ago - Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update - Business Wire
- 7 weeks ago - Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer - Seeking Alpha
- 2 months ago - Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields - Seeking Alpha
- 2 months ago - NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients - Benzinga
- 2 months ago - Novocure's pancreatic cancer treatment meets main goal in late-stage study - Reuters
- 2 months ago - Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer - Business Wire